Hans Edgar Bishop - Sep 8, 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Charles Newton, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Sep 8, 2022
Transactions value $
$14,538
Form type
4
Date filed
9/9/2022, 04:05 PM
Previous filing
Jul 7, 2022
Next filing
Oct 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Options Exercise $14.5K +145K +3.2% $0.10* 4.69M Sep 8, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Options Exercise $0 -145K -85.71% $0.00 24.2K Sep 8, 2022 Common Stock 145K $0.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.